Dr. Lee on Treatment Considerations in Smoldering Multiple Myeloma


In Partnership With:

Sarah S. Lee, MD, discusses treatment considerations in smoldering multiple myeloma.

Sarah S. Lee, MD, physician, Seattle Cancer Care Alliance, assistant professor, Division of Medical Oncology, University of Washington School of Medicine, assistant member, Clinical Research Division, Fred Hutchinson Cancer Research Center, discusses treatment considerations in smoldering multiple myeloma.

Because a significant amount of research is ongoing for patients with smoldering multiple myeloma, enrollment to clinical trials is often the highest priority, Lee explains. However, for high-risk patients who are ineligible for clinical trials, treatment with lenalidomide (Revlimid) may be considered.

Data from a phase 2/3 trial (NCT01169337) showed that early intervention with lenalidomide significantly delayed progression to symptomatic multiple myeloma and the development of end-organ damage vs observation in patients with smoldering multiple myeloma. Moreover, quality of life did not appear to be negatively affected with the addition of lenalidomide vs observation in this patient population, Lee concludes.

Related Videos
Kathryn Beckermann, MD, PhD
Eleonora Dondossola, PhD
William B. Pearse, MD
A panel of 5 experts on multiple myeloma
A panel of 5 experts on multiple myeloma
Pasi A. Jänne, MD, PhD, director, Lowe Center for Thoracic Oncology, director, Belfer Center for Applied Cancer Science, director, Chen-Huang Center for EGFR Mutant Lung Cancers, senior physician, David M. Livingston, MD, Chair, Dana-Farber Cancer Institute; professor, medicine, Harvard Medical School
Rachid Baz, MD, section head, Myeloma, Department of Malignant Hematology, Moffitt Cancer Center; co-director, Pentecost Family Myeloma Research Center
Harriet Kluger, MD, Harvey and Kate Cushing Professor of Medicine (Oncology) and of Dermatology; director, Yale SPORE in Skin Cancer; vice chair, Translational Research, Internal Medicine; chief, Division of Skin and Kidney Cancer; associate cancer center director, Education, Training and Faculty Development; deputy section chief, Medical Oncology, Yale Cancer Center
Robert DeBernardo, MD, section head, Obstetrics and Gynecology, Women’s Health Institute, Cleveland Clinic
Jacob Shreve, MD, MS, hematology/oncology fellow, Mayo Clinic